1. Home
  2. SNCR vs FATE Comparison

SNCR vs FATE Comparison

Compare SNCR & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNCR
  • FATE
  • Stock Information
  • Founded
  • SNCR 2000
  • FATE 2007
  • Country
  • SNCR United States
  • FATE United States
  • Employees
  • SNCR N/A
  • FATE N/A
  • Industry
  • SNCR EDP Services
  • FATE Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SNCR Technology
  • FATE Health Care
  • Exchange
  • SNCR Nasdaq
  • FATE Nasdaq
  • Market Cap
  • SNCR 101.2M
  • FATE 152.4M
  • IPO Year
  • SNCR 2006
  • FATE 2013
  • Fundamental
  • Price
  • SNCR $8.17
  • FATE $1.04
  • Analyst Decision
  • SNCR Strong Buy
  • FATE Hold
  • Analyst Count
  • SNCR 1
  • FATE 8
  • Target Price
  • SNCR $13.00
  • FATE $5.43
  • AVG Volume (30 Days)
  • SNCR 88.2K
  • FATE 2.1M
  • Earning Date
  • SNCR 05-06-2025
  • FATE 05-20-2025
  • Dividend Yield
  • SNCR N/A
  • FATE N/A
  • EPS Growth
  • SNCR N/A
  • FATE N/A
  • EPS
  • SNCR N/A
  • FATE N/A
  • Revenue
  • SNCR $172,842,000.00
  • FATE $13,631,000.00
  • Revenue This Year
  • SNCR $2.59
  • FATE N/A
  • Revenue Next Year
  • SNCR $4.91
  • FATE N/A
  • P/E Ratio
  • SNCR N/A
  • FATE N/A
  • Revenue Growth
  • SNCR 4.64
  • FATE N/A
  • 52 Week Low
  • SNCR $7.13
  • FATE $0.66
  • 52 Week High
  • SNCR $15.46
  • FATE $5.92
  • Technical
  • Relative Strength Index (RSI)
  • SNCR 35.91
  • FATE 46.67
  • Support Level
  • SNCR $7.69
  • FATE $0.91
  • Resistance Level
  • SNCR $11.13
  • FATE $1.34
  • Average True Range (ATR)
  • SNCR 0.78
  • FATE 0.13
  • MACD
  • SNCR -0.28
  • FATE -0.03
  • Stochastic Oscillator
  • SNCR 12.90
  • FATE 22.41

About SNCR Synchronoss Technologies Inc.

Synchronoss Technologies Inc is a leading provider of white-label cloud, messaging, digital and network management solutions that enable its customers to keep subscribers, systems, networks and content in sync. The Synchronoss Personal CloudTM solution is designed to create an engaging and trusted customer experience through ongoing content management and engagement. The Synchronoss Personal CloudTM platform is a secure and highly scalable, white-label platform that allows its customers' subscribers to backup and protect, engage with, and manage their personal content. The company derives revenue from subscriptions and transaction-based fees. A majority of the firm's revenue is generated in the United States, and the rest is from countries across the world.

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Share on Social Networks: